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Key Clinical Message
Patients with personal or family history of congenital hypothyroidism, and/or
neurological findings that also have chronic respiratory symptoms may have a
mutation in the NKX2.1 gene as the unifying cause of their disease. Brain–
lung–thyroid disease is the ensuing condition, which although rare, needs to be
part of the differential diagnosis.
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Introduction
The NKX2-1 is a gene that encodes the thyroid transcrip-
tion factor 1, a member of the homeodomain-containing
family of transcription factors. During human develop-
ment, NKX2-1 is expressed early in fetal life in the thyroid
bud and prosencephalon, and later in the lung epithelium
[1, 2] NKX2-1 is critical for the expression of surfactant
proteins A, B, and C, as well as ABCA3 [3–5], a lipid trans-
porter in pulmonary surfactant biogenesis. Haploinsuffi-
ciency for NKX2-1 due to either complete gene deletions or
loss-of-function mutations results in brain–thyroid–lung
syndrome with affected individuals having variable degrees
of pulmonary disease (neonatal respiratory distress syn-
drome or children’s interstitial lung disease), hypothy-
roidism, and neurologic abnormalities (typically benign
hereditary chorea) [6–11]. However, the classical triad is
not always present and severity of the thyroid, neurological,
and pulmonary disorders vary widely [8, 12]. In this report
we describe a family of two siblings, and their mother with
a NKX2-1 mutation that has not previously been associated
with lung disease. The mother signed an informed consent
for the publication of these cases.
Case Presentations
The mother of the two siblings described in this report
has congenital hypothyroidism (Fig. 1, II-2). She required
extracorporeal membrane oxygenation (ECMO) therapy
in the neonatal period for respiratory failure due to
meconium aspiration, she was discharged home without
supplemental oxygen and has not had any significant res-
piratory illnesses since then. She also has gait ataxia and
tremors which were attributed to brain injury following
ECMO therapy. The maternal aunt (Fig. 1, II-3) has
hypothyroidism but no respiratory or neurologic disease.
Both the mother and maternal aunt were found to carry
the same NKX2-1 gene variant as the proban case. The
maternal grandparents have no history of thyroid, neuro-
logic, or respiratory disease, and they do not carry this
gene variant.
Case 1
Our first encounter with the family was with the oldest
child (Fig. 1, III-1). She was born full term without com-
plications. Her newborn screen was positive for
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hypothyroidism, and she was started on thyroid hormone
replacement. At 4 months of age, she was admitted for
management of preseptal cellulitis. During that admission
she was found to have mild tachypnea, subcostal retrac-
tions, bilateral lung crackles, and an oxyhemoglobin satu-
ration ranging between 83% and 90% on room air. Initial
radiograph of the chest was unremarkable. Further work
up included high resolution computed tomography
(HRCT) of the chest, bronchoscopy, echocardiogram,
sleep study, video swallow study, and brain MRI. The
HRCT of the chest showed only some dependent atelecta-
sis, but normal lung parenchyma, the sleep study revealed
mild obstructive hypopnea that improved with oxygen
supplementation but no hypoventilation, and the video
swallow study revealed aspiration of thin liquids. The
child was discharged home on oxygen via nasal cannula
(1.5 L/min), thickened formula, and thyroid hormone
replacement. NKX2-1 gene analysis was reported as
heterozygous for an intronic variant, c.464-9C>A. This
mutation was considered a variant of uncertain signifi-
cance as it had not been previously reported in patients
or unaffected individuals; however, splice site calculators
indicated a potential reduction in correct splicing.
Over the next few months, her oxygen requirement
increased to 2 L/min. At 12 months the age she was
admitted with severe respiratory distress requiring endo-
tracheal intubation and mechanical ventilation due to
human metapneumovirus infection. She developed severe
ARDS requiring 2 weeks of ECMO therapy. She recovered
from this acute illness and was discharged home with
supplemental oxygen at 2.5 L/min via nasal cannula and
nasogastric tube feeding due to oral aversion.
She was admitted a third time at age of 20 months
with respiratory syncytial virus (RSV) bronchiolitis and
severe respiratory distress requiring endotracheal intuba-
tion and high frequency mechanical ventilation. Three
weeks later she was discharged with an increased oxygen
requirement of 3 L/min. A repeat swallow study during
this admission was normal. The child was seen in pul-
monary clinic at 22 months of age. At that time, respira-
tory rate was 70/min on 2 L/min supplemental oxygen,
oxyhemoglobin saturation on room air was 82%, and
lung examination showed severe retractions, and diffuse
crackles. A repeat HRCT of the chest showed diffuse
mixed ground-glass and ill-defined nodular opacities scat-
tered throughout both lungs. Treatment was begun with
triple anti-inflammatory therapy consisting of pred-
nisolone (2 mg/kg every other day), azithromycin 80 mg
three times a week, and hydroxychloroquine (6 mg/kg/
day). Two months later, the child showed significant
Figure 1. Pedigree. Filled symbols represent individuals testing positive for NKX2-1 c.464-9C>A.
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improvements in growth, respiratory rate, and lung exam-
ination. One year after initiating chronic anti-inflamma-
tory therapy, prednisolone dose had been weaned to
0.7 mg/kg every other day, oxygen therapy remained at
2 L/min, her oxyhemoglobin saturation had improved to
90% on room air, respiratory rate was 42/min, there were
no retractions, lung examination showed only sparse
crackles at the bases, and she had not required
hospitalizations.
Case 2
The younger sister (Fig. 1, III-2) was born to the same
parents at term without complications. She was also diag-
nosed with congenital hypothyroidism by newborn
screening and was started on thyroid hormone replace-
ment therapy soon after birth. She did not have any res-
piratory problem until 4 months of age when she
developed RSV bronchiolitis. During that illness she was
found to be hypoxemic and required oxygen therapy for
a few days, but discharged home on room air and with a
normal respiratory examination. Genetic testing for
NKX2-1 demonstrated the same variant as her older sis-
ter. She was admitted to a local hospital at the age of
7 months with pneumonia and was treated with antibi-
otics, during that admission she again required oxygen
supplementation. Upon follow-up in the pulmonary clinic
at 8 months of age, she was started on maintenance pred-
nisolone therapy of 2 mg/kg/day, which was weaned off
slowly without development of respiratory symptoms.
Discussion
The individuals from the family described in this report
possess a heterozygous NKX2-1 gene variant (c.464-9C>A;
p.Ile155Thrfs*286). Because the variant was located
within an intron and had not been previously linked to
brain–lung–thyroid syndrome, it was initially reported as
a variant of uncertain significance. However, the same
NKX2-1 variant was subsequently reported to be linked
to benign hereditary chorea in a Japanese family [13].
This family included six individuals in three generations
presenting with choreic involuntary movements in child-
hood, without thyroid or respiratory problems. Further
study of this variant found that it activates a cryptic splice
acceptor site, resulting in the insertion of seven nucleo-
tides in the transcript. This is predicted to cause a change
in the reading frame resulting in an abnormal protein
with amino acid substitutions beginning at amino acid
155. To our knowledge, this NKX2-1 mutation has not
been reported in association with lung disease previously.
A molecular defect in the NKX2-1 gene was first identi-
fied in 1998 in a patient with neonatal thyroid dysfunction
and respiratory failure, who later developed hypotonia and
truncal ataxia [7]. Subsequently other cases were described,
and the term “Brain–Thyroid–Lung syndrome” was coined
in 2005 [8–11]. Since then this term has become widely
used to describe patients who have neurological, thyroid,
and/or lung disorders in association with NKX2-1 gene
mutations [8, 12]. The classical triad of this syndrome is
not always present, as can be appreciated in the family
described in this report; and the severity of neurological,
thyroid, and lung compromise is also variable [10]. The
lung disease may present as respiratory distress syndrome,
interstitial lung disease, pulmonary fibrosis, or recurrent
respiratory tract infections [11, 14–18].
In the family we describe in this report, we have not only
observed variation in the organ systems involved, but also a
variable degree of lung disease, this is consistent with the
findings of Hanvas et al. in a case series of 21 patients with
different NKX2-1 mutations and variable degree of lung
disease recently reported [10]. The same observation was
noted with regard to thyroid and neurological involvement
by Gras et al., who concluded that there were no genotype–
phenotype correlations, and that there was phenotype vari-
ability in individuals with the same mutation [14]. Hanvas
et al. also reported that recurrent pulmonary infections
were a prominent feature in patients with NKX2-1 muta-
tions [10], this phenomenon can also be appreciated in the
proband case of our report.
The patients’ maternal grandparents both tested nega-
tive for the familial NKX2-1 variant, but had two children
(the patients’ mother and maternal aunt) who tested pos-
itive for the variant. It is then likely that one of the
grandparents is mosaic for the variant, which was not
detectable in DNA extracted from a blood sample. How-
ever, the possibility of misattributed parentage was not
specifically excluded.
Hydroxychloroquine has been successfully used in the
treatment of both surfactant protein C and ABCA3 defi-
ciencies [19, 20]. Since the transcription factor NKX2-1
regulates the expression of both surfactant protein C and
ABCA3, we reasoned that hydroxychloroquine would be
useful in the treatment of brain–lung–thyroid disease
associated with an NKX2-1 mutation. Therapy with
hydroxychloroquine, along with azithromycin and pred-
nisolone, was associated with significant clinical improve-
ment in the sibling with life-threatening lung disease. As
far as we are aware, this is the first report of seemingly
successful treatment of NKX2-1 associated lung disease
with this combination therapy, but given the variable
phenotypic manifestations of lung involvement in infants
with this condition, and the fact that our patient was
recovering from a severe pulmonary viral infections, our
ability to state with a high degree of certainty that this
drug therapy improved the underlying lung disease is
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limited. On the other hand her symptoms responded
promptly, and she has been doing well since then suggest-
ing that this intervention has played a role.
Conclusion
Mutations in the NKX2-1 gene result in variable disease
phenotypes. The classical triad of brain–thyroid–lung syn-
drome is not always present, and different presentations
may result from same mutations. A high index of suspi-
cion should be maintained in patients with lung disease
of unknown cause, especially if there is associated neuro-
logical or thyroid disease or a family history of such dis-
orders. In this report, we show that the c.464-9C>A
variant in the NKX2-1 gene can be associated with life-
threatening infantile lung disease, and that treatment with
hydroxychloroquine, azithromycin, and prednisolone
might be helpful in such cases.
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